Hypervariable epitope construct: A synthetic immunogen that overcomes MHC restriction of antigen presentation

Molecular Immunology

Volumn 36, Issue 10, 1999, Pages 631-637

  Meyer, Debra ^a   Torres, José V ^b  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; HEC; MHC restriction; Peptide immunogen; Vaccine

Indexed keywords

ENVELOPE PROTEIN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGLOBULIN VARIABLE REGION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN PRESENTATION; CELLS, CULTURED; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; GENE PRODUCTS, ENV; H-2 ANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED STRAINS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0032827476     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00080-2     Document Type: Article

References (23)

1. Alexander J., Fikes J., Hoffman S., Franke E., Sacci J., Appella E., Chisari F.V., Guidotti L.G., Chesnut R.W., Livingston B., Sette A. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Research. 18:(2):1998;79-92.
2. Anderson D.E., Malley A., Benjamini E., Gardner M.B., Torres J.V. Hypervariable epitope constructs as a means of accounting for epitope variability. Vaccine. 12:1994;736-739.
3. Gairin J.E., Oldstone M.B. Design of high affinity MHC-specific antagonist peptides that inhibit CTL activity: implications for control of viral disease. J. Virol. 66:1992;6755-6762.
4. Gairin J.E., Oldstone M.B. Virus and cytotoxic T lymphocytes: crucial role of viral peptide secondary structure in major histocompatibility complex class I interactions. J. Virol. 67:1993;2903-2907.
5. Hislop A.D., Good M.F., Mateo L., Gardner J., Gatei M.H., Daniel R.C., Meyers B.V., Lavin M.F., Suhrbier A. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nat. Med. 4:1998;1193-1196.
6. Kabeya H., Ohashi K., Ohishi K., Sugimoto C., Amanuma H., Onuma M. An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep. Vaccine. 14:1996;1118-1122.
7. Kaumaya P.T.P., Feng N., Seo H.Y., Kobs-Conrad S.F., Van-Buskirk A.M., Sheridan J.F. Smith J.A., Rivier J. Peptides: Chemistry and Biology. 1992;883 ESCOM, Leiden, The Netherlands.
8. Kaumaya P.T.P., Kobs-Conrad S., DiGeorge S., Stevens V. Anantharamaiah G., Basawa C. Peptides: Design, Synthesis and Biology. 1994;133 Springer-Verlag, New York.
9. Lairmore M.D., DiGeorge A.M., Conrad S.F., Trevino A.V., Lal R.B., Kaumaya P.T. Human T lymphotropic Virus Type 1 peptides in chimeric and multivalent constructs with promiscuous T cell epitopes enhance immunogenicity and overcome genetic restriction. J. Virol. 69:1995;6077-6089.
10. Ljunggren H-G., Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162:1985;1745-1759.
11. Ljunggren H-G., Stam N.J., Ohlen C., Neefjes J.J., Hoglund P., Heemels M-T., Bastin J., Schumacher T.N., Townsend A., Karre K., Ploegh H.L. Empty MHC class I molecules come out in the cold. Nature. 346:1990;476-480.
12. Lockyer M.J., Cooper H., Tite J., Rowan W., Crowe J.S. Immunogenicity of hybrid Plasmodium falciparum malaria antigen. Parasitology. 106:1993;451-457.
13. Meyer D., Anderson D.E., Gardner M.B., Torres J.V. Hypervariable epitope constructs (HEC) representing variability in gp130 of SIV induce a broad humoral immune response in rabbits and Rhesus macaques. AIDS Res. Hum. Retro. 14:(9):1998;749-760.
14. Meyer D., Torres J.V. Induction of cytotoxic and helper T cell responses by modified variability peptides. Viral Immunology. 12:(2):1999;117-129.
15. Oldstone M.B., Lewicki H., Borrow P., Hudrisier D., Gairin J.E. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J. Virol. 69:1995;7423-7429.
16. Ozato K., Hansen T.H., Sachs D.H. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 125:1980;2473-2477.
17. Ramos T., Möller E., Möller G. Induction of immunity and suppression by haptenated self structures. Immunol. Rev. 50:1980;227-273.
18. Russell-Jones G., Sullivan J.S., Geczy A.F. Peptide sequences with strong stimulatory activity for lymphoid cells: implications for vaccine development. Vaccine. 11:1993;1310-1315.
19. Seo Y.S., Kobs-Conrad S., Kaumaya P. Schneider C., Eberle A. Peptides. 1993;866 ESCOM Scientific Publications, Leiden, The Netherlands.
20. Threlkeld S.C., Wentworth P.A., Kalams S.A., Wilkes B.M., Ruhl D.J., Keogh E., Sidney J., Southwood S., Walker B.D., Sette A. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. Journal of Immunology. 159:(4):1997;1648-1657.
21. Torres J.V., Malley A., Banapour B., Anderson D.E., Axthelm M.K., Gardner M.B., Benjamini E. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. AIDS Res. Hum. Retro. 9:1993;423-428.
22. Townsend A.R.M., Bodner H. Antigen recognition by class I-restricted T-lymphocytes. Annu. Rev. Immunol. 7:1989;601-624.
23. Zinkernagel R.M., Doherty P.C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27:1979;51-177.